Second, using validated in vivo biomarkers of Aβ, tau and α-syn pathology, we examined how AD, LB, and the combined AD+LB pathologies drove elevated brain ages that deviated from typical aging. The gene discussed is MAPT; the disease is Alzheimer disease.